Glesatinib is under clinical development by Mirati Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Glesatinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Glesatinib (MGCD-265) was under development for the treatment of squamous cell carcinoma of the head and neck (HNSCC), papillary renal carcinoma, gastric cancer, non-small cell lung cancer and other solid tumours. The drug candidate is administered orally. The drug candidate targets unique spectrum of receptor tyrosine kinases c-MET and AXL.
Mirati Therapeutics overview
Mirati Therapeutics is a clinical-stage oncology company that developing novel therapeutics to address the genetic and immunological promoters of cancer. The company product pipeline includes Adagrasib (MRTX849), an oral small molecule inhibitor of KRASG12C and MRTX1133, a potent small molecule inhibitor of the KRASG12D for the treatment of colorectal and pancreatic cancer. Mirati Therapeutics is also evaluating Sitravatinib, a multi kinase inhibitor against non-small cells lung cancer in non-smokers and MRTX1719 to treat MTAP deleted cancers. The company has partner with Zai Lab, Beigene, Sanofi, Boehringer, Novartis and Bristol Myers Squibb, among others. It operates in Canada, Netherlands and the US. Mirati Therapeutics is headquartered in San Diego, California, the US.
For a complete picture of Glesatinib’s drug-specific PTSR and LoA scores, buy the report here.